Bridgebio Oncology Therapeutics Stock Performance
| BBOT Stock | 13.19 0.11 0.83% |
On a scale of 0 to 100, BridgeBio Oncology holds a performance score of 5. The firm shows a Beta (market volatility) of 0.42, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BridgeBio Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding BridgeBio Oncology is expected to be smaller as well. Please check BridgeBio Oncology's potential upside, and the relationship between the total risk alpha and kurtosis , to make a quick decision on whether BridgeBio Oncology's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BridgeBio Oncology Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady basic indicators, BridgeBio Oncology unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.83) | Five Day Return 7.15 | Year To Date Return 7.32 | Ten Year Return 29.44 | All Time Return 29.44 |
1 | A key Trump ally won an election. It could be good news for US taxpayers - CNN | 10/27/2025 |
2 | BBOT to Participate in the Jefferies Global Healthcare Conference in London | 11/03/2025 |
3 | BridgeBio Oncology Therapeutics, Inc. GAAP EPS of -1.03 | 11/13/2025 |
4 | BBOT to Participate in Upcoming December Investor Healthcare Conferences | 11/18/2025 |
5 | Here are Fridays biggest analyst calls Nvidia, Apple, CoreWeave, Broadcom, Alphabet, Netflix, more | 12/05/2025 |
6 | BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RASPI3K Breaker, at the San Antonio Breast Cancer Symposium | 12/10/2025 |
7 | BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635 | 12/11/2025 |
8 | BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference | 12/16/2025 |
9 | Acquisition by Eli Wallace of 1114400 shares of BridgeBio Oncology at 12.52 subject to Rule 16b-3 | 12/31/2025 |
10 | BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3K Pipeline Programs | 01/07/2026 |
11 | BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com | 01/09/2026 |
| Begin Period Cash Flow | 250 K | |
| Total Cashflows From Investing Activities | -184 M |
BridgeBio | Build AI portfolio with BridgeBio Stock |
BridgeBio Oncology Relative Risk vs. Return Landscape
If you would invest 1,146 in BridgeBio Oncology Therapeutics on October 12, 2025 and sell it today you would earn a total of 173.00 from holding BridgeBio Oncology Therapeutics or generate 15.1% return on investment over 90 days. BridgeBio Oncology Therapeutics is currently generating 0.3126% in daily expected returns and assumes 4.2489% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than BridgeBio, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BridgeBio Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BridgeBio Oncology Therapeutics, and traders can use it to determine the average amount a BridgeBio Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0736
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BBOT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average BridgeBio Oncology is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BridgeBio Oncology by adding it to a well-diversified portfolio.
BridgeBio Oncology Fundamentals Growth
BridgeBio Stock prices reflect investors' perceptions of the future prospects and financial health of BridgeBio Oncology, and BridgeBio Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BridgeBio Stock performance.
| Current Valuation | 856.64 M | ||||
| Shares Outstanding | 79.2 M | ||||
| EBITDA | (80.66 M) | ||||
| Net Income | 7.6 M | ||||
| Total Debt | 5.71 M | ||||
| Book Value Per Share | (403.34) X | ||||
| Cash Flow From Operations | (763.82 K) | ||||
| Earnings Per Share | (1.11) X | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 194.42 M | ||||
| Retained Earnings | (3.73 M) | ||||
| Working Capital | 139.11 M | ||||
About BridgeBio Oncology Performance
Assessing BridgeBio Oncology's fundamental ratios provides investors with valuable insights into BridgeBio Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the BridgeBio Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.37) | (0.36) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.35) | (0.34) |
Things to note about BridgeBio Oncology performance evaluation
Checking the ongoing alerts about BridgeBio Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BridgeBio Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BridgeBio Oncology had very high historical volatility over the last 90 days | |
| BridgeBio Oncology has high likelihood to experience some financial distress in the next 2 years | |
| BridgeBio Oncology Therapeutics was previously known as HLXB Old and was traded on NASDAQ Exchange under the symbol HLXB. | |
| BridgeBio Oncology generates negative cash flow from operations | |
| BridgeBio Oncology has a frail financial position based on the latest SEC disclosures | |
| About 24.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: BridgeBio Oncology stock initiated with Outperform rating at Raymond James - Investing.com |
- Analyzing BridgeBio Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BridgeBio Oncology's stock is overvalued or undervalued compared to its peers.
- Examining BridgeBio Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BridgeBio Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BridgeBio Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BridgeBio Oncology's stock. These opinions can provide insight into BridgeBio Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BridgeBio Stock Analysis
When running BridgeBio Oncology's price analysis, check to measure BridgeBio Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Oncology is operating at the current time. Most of BridgeBio Oncology's value examination focuses on studying past and present price action to predict the probability of BridgeBio Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Oncology's price. Additionally, you may evaluate how the addition of BridgeBio Oncology to your portfolios can decrease your overall portfolio volatility.